Nav1.7 is a voltage-gated sodium-channel alpha subunit encoded by [SCN9A](/proteins/scn9a-protein). It is highly expressed in nociceptive dorsal-root-ganglion [neurons](/entities/neurons) and other peripheral sensory compartments, where it acts as a threshold amplifier for action-potential initiation.[@emery2016][@shen2019] Human genetics established Nav1.7 as one of the clearest causal pain targets in medicine: loss-of-function variants cause congenital insensitivity to pain, while gain-of-function variants drive severe pain syndromes such as inherited erythromelalgia and related channelopathies.[@cox2006][@zhang2014]
Because of this unusually strong genotype-phenotype validation, Nav1.7 remains a major non-opioid analgesic target and a benchmark model for precision ion-channel therapeutics.[@emery2016][@xue2021][@dormer2023]
Nav1.7 is a voltage-gated sodium-channel alpha subunit encoded by [SCN9A](/proteins/scn9a-protein). It is highly expressed in nociceptive dorsal-root-ganglion [neurons](/entities/neurons) and other peripheral sensory compartments, where it acts as a threshold amplifier for action-potential initiation.[@emery2016][@shen2019] Human genetics established Nav1.7 as one of the clearest causal pain targets in medicine: loss-of-function variants cause congenital insensitivity to pain, while gain-of-function variants drive severe pain syndromes such as inherited erythromelalgia and related channelopathies.[@cox2006][@zhang2014]
Because of this unusually strong genotype-phenotype validation, Nav1.7 remains a major non-opioid analgesic target and a benchmark model for precision ion-channel therapeutics.[@emery2016][@xue2021][@dormer2023]
Molecular Architecture And Channel Function
Nav1.7 follows the canonical Nav architecture (four homologous domains with six transmembrane segments each), with voltage sensing in S1-S4 and pore/selectivity modules in S5-S6.[@shen2019] Cryo-EM structures of human Nav1.7 in complex with auxiliary subunits and toxins provided high-resolution templates for rational inhibitor design and state-dependent ligand development.[@shen2019]
Biophysically, Nav1.7 is positioned to amplify small depolarizations toward firing threshold. This “gain control” behavior explains why modest kinetic shifts can yield major pain phenotypes in patients with pathogenic SCN9A variants.[@cox2006][@zhang2014]
Physiologic Role
Key roles include:
Setting excitability thresholds in nociceptors.
Supporting repetitive firing in peripheral pain pathways.
Contributing to olfactory signaling (consistent with anosmia in complete loss-of-function cases).[@cox2006][@xue2021]
In translational terms, Nav1.7 is attractive because it is comparatively peripheral-dominant relative to many CNS sodium channels, offering a plausible route to analgesia with fewer central adverse effects when selectivity is sufficient.[@emery2016][@xue2021]
Disease Relevance
Pain channelopathies
Nav1.7 sits at the center of a continuum from pain loss to pain amplification:
Loss-of-function: congenital inability to experience pain.[@cox2006]
Gain-of-function: inherited erythromelalgia and related severe pain disorders.[@zhang2014][@brenn2024]
Mixed/partial effects: variable penetrance syndromes, including some ocular and small-fiber pain phenotypes.[@brenn2024]
Relevance to neurodegeneration projects
Nav1.7 is not a primary monogenic driver of [Alzheimer's disease](/diseases/alzheimers-disease) or [Parkinson's disease](/diseases/parkinsons-disease), but it is clinically relevant in neurodegeneration-adjacent domains:
Pain symptom burden in chronic neurodegenerative disease cohorts.
Peripheral neuropathy frameworks used in differential diagnosis and monitoring.
Shared principles for targeting excitability without destabilizing broader network function.[@emery2016][@xue2021][@dormer2023]
Therapeutic Targeting And Trial Landscape
Despite very strong target genetics, clinical translation has been difficult, mainly due to selectivity constraints versus other Nav isoforms and the complexity of state-dependent blockade in human pain circuits.[@emery2016][@xue2021][@dormer2023]
Current strategy themes include:
Isoform- and state-selective small molecules.
Peripheral restriction to reduce CNS liabilities.
Genotype-informed patient stratification in trials.[@xue2021][@dormer2023]
Recent trial-focused reviews indicate continued activity in Nav1.7 programs with improving structure-guided medicinal chemistry, but emphasize the gap between strong target rationale and consistently robust clinical efficacy signals.[@dormer2023]
Implementation Notes For Mechanistic Reasoning
For NeuroWiki ranking workflows, Nav1.7 is a high-confidence “causal target” in pain biology but a context-dependent target in neurodegeneration. Evidence should therefore be interpreted as:
High for nociceptive channelopathy causality.
Moderate for broad chronic-pain pharmacology.
Exploratory for direct disease-modifying roles in classical neurodegenerative proteinopathies.
[Guide to Pharmacology: Nav1.7](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=634)
References
[Emery EC et al, Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief (2016)](https://pubmed.ncbi.nlm.nih.gov/26941184/)
[Shen H et al, Structures of human Na(v)1.7 channel in complex with auxiliary subunits and animal toxins (2019)](https://pubmed.ncbi.nlm.nih.gov/30765606/)
[Cox JJ et al, An SCN9A channelopathy causes congenital inability to experience pain (2006)](https://pubmed.ncbi.nlm.nih.gov/17167479/)
[Zhang Z et al, Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia (2014)](https://pubmed.ncbi.nlm.nih.gov/29911575/)
[Xue Y et al, Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models (2021)](https://pubmed.ncbi.nlm.nih.gov/33775738/)
[Dormer A et al, A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37168847/)
[Brenn D et al, Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7) (2024)](https://pubmed.ncbi.nlm.nih.gov/37721535/)